Patents by Inventor Preben Houlberg Olesen

Preben Houlberg Olesen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Haloalkylsulfone substituted compounds useful for treating obesity and diabetes
    Patent number: 7939690
    Abstract: The present invention relates to novel compounds of formula [I], wherein R1 represents heteroaryl, at least one substituent among R5, R6 and R7 represent —SR12, —S(O)R12 or —S(O)2R12 and the remaining substituents are as defined in the claims, that act as chemical uncouplers. Compounds of the invention are useful inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases associated therewith.
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: May 10, 2011
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Anders Klarskov Petersen, Preben Houlberg Olesen, Lise Brown Christiansen, Flemming Elmelund Nielsen
  • 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
    Patent number: 7915299
    Abstract: The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful, inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith.
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: March 29, 2011
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Anders Klarskov Petersen, Preben Houlberg Olesen, Lise Brown Christiansen, Holger Claus Hansen, Flemming Elmelund Nielsen
  • 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES
    Publication number: 20100249161
    Abstract: The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful, inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith.
    Type: Application
    Filed: November 15, 2007
    Publication date: September 30, 2010
    Inventors: Anders Klarskov Petersen, Preben Houlberg Olesen, Lise Brown Christiansen, Holger Claus Hansen, Flemming Elmelund Nielsen
  • HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES
    Publication number: 20100113536
    Abstract: The present invention relates to novel compounds of formula [I], wherein R1 represents heteroaryl, at least one substituent among R5, R6 and R7 represent —SR12, —S(O)R12 or —S(O)2R12 and the remaining substituents are as defined in the claims, that act as chemical uncouplers. Compounds of the invention are useful inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases associated therewith.
    Type: Application
    Filed: November 15, 2007
    Publication date: May 6, 2010
    Inventors: Anders Klarskov Petersen, Preben Houlberg Olesen, Lise Brown Christiansen, Flemming Elmelund Nielsen
  • NOVEL 2-(2-HYDROXYPHENYL)BENZIMlDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES
    Publication number: 20100063122
    Abstract: The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful, inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith.
    Type: Application
    Filed: November 15, 2007
    Publication date: March 11, 2010
    Inventors: Anders Klarskov Peterson, Preben Houlberg Olesen, Lise Brown Christiansen, Holger Claus Hansen, Flemming Elmelund Nielsen
  • HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES
    Publication number: 20100041657
    Abstract: The present invention relates to compounds of formula I, in which at least one of R5, R6 and R7 is SR12, S(O)R12 or S(O)2R12 group where R12 is a C1-6haloalkyl group, that act, as chemical uncouplers. Compounds of the invention are useful in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith.
    Type: Application
    Filed: May 11, 2006
    Publication date: February 18, 2010
    Applicant: NOVO NORDICK A/S
    Inventors: Preben Houlberg Olesen, Holger Claus Hansen, Lise Brown Christiansen, Flemming Elmelund Nielsen, Anders Klarskov Petersen
  • Salicylic anilides
    Patent number: 7645791
    Abstract: Novel salicylic anilides are chemical uncouplers useful e.g. for the treatment of obesity.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: January 12, 2010
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Preben Houlberg Olesen, Thomas Kruse Hansen, Lise Brown Christiansen, Holger Claus Hansen
  • NOVEL 2-(2-HYDROXYPHENYL) BENZOTHIADIAZINES USEFUL FOR TREATING OBESITY AND DIABETES
    Publication number: 20090325941
    Abstract: The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful, inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith.
    Type: Application
    Filed: November 15, 2007
    Publication date: December 31, 2009
    Inventors: Anders Klarskov Petersen, Preben Houlberg Olesen, Lise Brown Christiansen, Holger Claus Hansen, Flemming Elmelund Nielsen
  • Novel Haloalkoxy-Substituted Salicylic Anilides
    Publication number: 20090062396
    Abstract: The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful in the treatment, including prevention, of obesity, diabetes and a number of diseases or disorders associated therewith.
    Type: Application
    Filed: May 23, 2006
    Publication date: March 5, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Preben Houlberg Olesen, Holger Claus Hansen, Lise Brown Christiansen, Anders Klarskov Petersen, Flemming Elmelund Nielsen, Birgit Sehested Hansen
  • Novel Salicylic Anilides
    Publication number: 20090005434
    Abstract: Novel salicylic anilides are chemical uncouplers useful e.g. for the treatment of obesity.
    Type: Application
    Filed: June 27, 2008
    Publication date: January 1, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Preben Houlberg Olesen, Thomas Kruse Hansen, Lise Brown Christiansen, Holger Claus Hansen
  • Sulfonamide Derivatives
    Publication number: 20080255240
    Abstract: Novel sulfon amide derivatives are chemical uncouplers useful e.g. for the treatment of obesity.
    Type: Application
    Filed: May 4, 2005
    Publication date: October 16, 2008
    Applicant: Novo Nordisk A/S
    Inventors: Lise Brown Christiansen, Preben Houlberg Olesen, Holger Claus Hansen
  • Novel Trifluoromethoxy-Substituted Aryl Anilides
    Publication number: 20080234381
    Abstract: The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful in the treatment, including prevention, of obesity, diabetes and a number of diseases or disorders associated therewith.
    Type: Application
    Filed: May 23, 2006
    Publication date: September 25, 2008
    Applicant: Novo Nordisk A/S
    Inventors: Preben Houlberg Olesen, Holger Claus Hansen, Lise Brown Christiansen, Anders Klarskov Petersen, Flemming Elmelund Nielsen, Birgit Sehested Hansen
  • Novel Indole Derivatives
    Publication number: 20080113944
    Abstract: 5-vinyl-indole derivatives are chemical uncouplers useful e.g. for the treatment of obesity.
    Type: Application
    Filed: May 3, 2005
    Publication date: May 15, 2008
    Applicant: Novo Nordisk A/S
    Inventors: Preben Houlberg Olesen, Rolf Hohlweg
  • Non-peptide GLP-1 agonists
    Patent number: 6927214
    Abstract: Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: August 9, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Min Teng, Larry Kenneth Truesdale, Dilip Bhumralkar, Dan Kiel, Michael D. Johnson, Christine Thomas, Anker Steen Jorgensen, Peter Madsen, Preben Houlberg Olesen, Liselotte Bjerre Knudsen, Ingrid Vivika Petterson, Johannes Cornelis de Jong, Carsten Behrens, Janos Tibor Kodra, Jesper Lau
  • Halo sulfonyl aryl boronates
    Patent number: 6872849
    Abstract: The present invention relates to halo sulfonyl aryl boronates of the general formula (I): wherein Arylene designates a carbocyclic or heterocyclic, aromatic ring system comprising 1-3 rings; R1, R2 and R3 are, independently, hydrogen, C1-6alkyl, C1-6alkoxy, halogen, nitro, cyano or phenyl; X is fluoro, chloro or bromo; and Y is a boroxine moiety attached via a bond from Arylene to one of the boron atoms of a boroxine ring which ring has a group of the formula -Arylene(R1)(R2)(R3)SO2X, wherein Arylene, R1, R2, R3 and X are as defined above, at each of the other two boron atoms of the boroxine ring, or Y is a boronic acid group or a boronic ester group. The invention also relates to the preparation of the compounds of formula (I) and to their use in organic synthesis.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: March 29, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Per Vedso, Preben Houlberg Olesen, Thomas Hoeg-Jensen
  • Halo sulfonyl aryl boronates
    Publication number: 20040116701
    Abstract: The present invention relates to halo sulfonyl aryl boronates of the general formula (I): 1
    Type: Application
    Filed: October 30, 2003
    Publication date: June 17, 2004
    Inventors: Per Vedso, Preben Houlberg Olesen, Thomas Hoeg-Jensen
  • Use of 2,4-diaminothiazole derivatives
    Publication number: 20010039275
    Abstract: 2,4-Diaminothiazole derivatives which inhibit GSK-3 (glycogen synthase kinase-3) and which are useful for the treatment and/or prevention disorders and diseases wherein an inhibition of GSK-3 is beneficial, especially especially Alzheimer's disease, bipolar disorder, IGT (impaired glucose tolerance), Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Application
    Filed: January 31, 2001
    Publication date: November 8, 2001
    Inventors: Andrew Neil Bowler, Preben Houlberg Olesen, Anders Robert Sorensen, Bo Falck Hansen, Helle Worsaae, Peter Kurtzhals
  • Substituted azacyclic or azabicyclic compounds
    Patent number: 6022868
    Abstract: Disclosed are compounds of formula (I) selected from the following ##STR1## wherein Y is ##STR2## and wherein A, B, C, D, R, k, m, n, o, p, s, t and u are as defined in the specification. These compounds are useful in treating diseases in the central nervous system related to malfunctioning of the nicotinic cholinergic system.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: February 8, 2000
    Assignee: Novo Nordisk Als
    Inventors: Preben Houlberg Olesen, John Bondo Hansen
  • Substituted azacyclic compounds
    Patent number: 5994373
    Abstract: The present invention relates to therapeutically active heterocyclic compounds, to methods for their preparation and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system related to malfunctioning of the nicotinic cholinergic system.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: November 30, 1999
    Assignee: Novo Nordisk A/S Novo Alle DK 2880
    Inventor: Preben Houlberg Olesen
  • Heterocyclic compounds, their preparation and use
    Patent number: 5945417
    Abstract: The present invention relates to a method of treating a disease in the central nervous system via the metabotropic glutamate receptor system, the use of the known as well as novel pyridino(2,3-b) indoles (formula Ib) for the preparation of a medicament for treating said diseases, novel therapeutic active pyridino(2,3-b) indoles, a method for preparing the same and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: January 21, 1998
    Date of Patent: August 31, 1999
    Assignee: Novo Nordisk
    Inventors: Preben Houlberg Olesen, Anders Kanstrup